Men with a family history of prostate cancer and African-American men are particularly susceptible to the disease, with a twofold to sevenfold increased risk. Assessing risk in these populations has been difficult.
"There have been years of effort to try to identify genes and genetic mutations associated with prostate cancer as there are for breast cancer," said Veda N. Giri, M.D., director of the Prostate Cancer Risk Assessment Program (PRAP) at Fox Chase Cancer Center, Philadelphia. "Prostate cancer is a more genetically complex disease."
Giri and colleagues studied patients who are part of the center's Prostate Cancer Risk Assessment Program, an early detection program for men with a high prostate cancer risk. More than 700 participants are enrolled; 60 percent are African-American.
The investigators evaluated the clinical characteristics of men at high risk for prostate cancer; those who carry five genetic single nucleotide polymorphisms (SNPs) that have been associated with prostate cancer in recent studies. These genetic changes have mostly been reported in predominantly Caucasian populations and are being studied in African-American men as well.
"We are interested in looking at how these genetic risk markers can be used for assessing the risk for prostate cancer in high-risk men," said Giri. "These are men who have not yet developed prostate cancer, such as African-American men and men with family members with the disease. Can these markers be used as an indicator of upcoming prostate cancer?"
The men enrolled in PRAP are aged 35 to 69 years and meet one of the following criteria: one first-degree relative with prostate cancer or two second-degree relatives with prostate cancer on the same side of the family. The group also includes African-American men with BRCA 1/2 mutations.
Giri and colleagues compared the Caucasian high-risk men in PRAP with a control group, an all-Caucasian set of men who have no family or personal history of the disease. The men in the control group are at low risk for developing prostate cancer. Analysis revealed that while there was an effect found for increased risk for prostate cancer in Caucasian men at high-risk for several of these markers, none of the results were statistically significant. This could be related to the low sample size used in the study. When comparing these five genetic markers in high-risk Caucasian men with men already diagnosed with prostate cancer, the distribution of the markers was similar. This might indicate that these markers are clinically useful in Caucasian men at risk for prostate cancer, although further study is needed.
"When we compared African-American men in PRAP to the high-risk Caucasian men in PRAP, we did find a difference," she said. "African-American men tended to carry more of these genetic risk markers compared to the Caucasian men. Since African-American men carry more of these particular genetic markers, they may be more informative for prostate cancer risk assessment in African-American men."
The researchers then studied how these markers influence time to prostate cancer diagnosis. "We found a trend that African-American men who carried more of these risk markers tended to develop prostate cancer earlier," Giri said. This finding did not reach statistical significance.
Giri said the take-home message from this study is that genetic markers associated with prostate cancer risk need to be characterized in prospective screening populations in order to determine how to incorporate them into risk assessment for prostate cancer, particularly for men at high-risk for the disease. "These markers may have significant use in personalizing the early detection of prostate cancer in men at high-risk in order to provide tailored recommendations for screening and diagnosis of this disease," said Giri.
Source: American Association for Cancer Research
Related stories:
Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot'
Molecules of sugar sitting on the surface of cancer cells are keys to the development of a new vaccine aimed at both treating and stopping the spread of certain types of cancers called carcinomas, which include prostate, breast, ovarian and lung, among others. Armed with a new two-year grant for $600,000 from the Gateway for Cancer Research, an Illinois-based philanthropic foundation, immunologist Alessandra Franco, M.D., Ph.D., and her co-workers at the Moores Cancer Center at the University of California, San Diego are hoping to develop a low-cost immunotherapy for prostate carcinoma that may also have use against a variety of other carcinomas as well.
Team finds breast cancer gene linked to disease spread
A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death.
Family history of prostate cancer does not affect some treatment outcomes
In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according to a January 1 study in the
International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology.
Young blood fights cancer
"New blood" can revitalize a company or a sports team. Recent research by Tel Aviv University finds that young blood does a body good as well, especially when it comes to fighting cancer.
Gay and bisexual African-American men have the lowest use of prostate testing
Gay and bisexual black men are less likely to be tested for prostate cancer than men of any other racial and ethnic backgrounds regardless of their sexual orientation, according to a recent study by a researcher at Charles Drew University of Medicine and Science.
Should Anyone Still Take Vitamin E?
Researchers at UC Berkeley discovered vitamin E in 1922, and since then countless studies have been done on this still mysterious substance. Because its chief function seems to be as an antioxidant, neutralizing potentially harmful free radicals in the body, E became a superstar as the antioxidant theory of disease gained wider and wider attention.
Pre-existing diabetes for persons diagnosed with cancer associated with increased risk of death
Patients with diabetes at the time of a cancer diagnosis have an increased risk of death compared to patients without diabetes, according to a meta-analysis of studies reported in the December 17 issue of JAMA.
Low-income men more likely to be diagnosed with advanced prostate cancer
Low-income men are more likely to present with advanced prostate cancers, most likely because they don't receive screening services shown to reduce the diagnosis of later-stage cancers, a UCLA study found.